Completed PHASE3 INTERVENTIONAL 2-arm NCT02303769

Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS (GL2702)

A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS

Sponsor: GL Pharm Tech Corporation

Conditions Benign Prostatic Hyperplasia

Interventions Tamsulosin HCL 0.2mg Tamsulosin HCL 0.4mg

Updated 6 times since 2017 Last updated: Feb 24, 2016 Started: Mar 31, 2014 Primary completion: May 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Benign Prostatic Hyperplasia and is currently completed. GL Pharm Tech Corporation leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GL Pharm Tech Corporation

Data source: GL Pharm Tech Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea